Last update 02 Apr 2025

Amezalpat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
TPST 1120, TPST-1120
Target
Action
inhibitors
Mechanism
PPARα inhibitors(Peroxisome proliferator-activated receptor α inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC34H41N3O4
InChIKeyKUPVZYDOHAPPNF-UHFFFAOYSA-N
CAS Registry1616372-41-8

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic hepatocellular carcinomaPhase 3-29 Mar 2025
Unresectable Hepatocellular CarcinomaPhase 3-29 Mar 2025
Liver AbscessPhase 2
United States
01 Nov 2020
Liver AbscessPhase 2
China
01 Nov 2020
Liver AbscessPhase 2
France
01 Nov 2020
Liver AbscessPhase 2
Israel
01 Nov 2020
Liver AbscessPhase 2
New Zealand
01 Nov 2020
Liver AbscessPhase 2
Taiwan Province
01 Nov 2020
Primary Malignant Liver NeoplasmPhase 2
United States
01 Nov 2020
Primary Malignant Liver NeoplasmPhase 2
China
01 Nov 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
-
xwtqlpgwmq(qwxpixtflk) = yxokosppqc ixtelhovgj (rngcibfdlr )
Positive
20 Jun 2024
xwtqlpgwmq(qwxpixtflk) = abodspthwb ixtelhovgj (rngcibfdlr )
Phase 1
38
reaxlwybtw(ohuzpvhfqo) = The most common were grade 1-2 nausea, fatigue, and diarrhea. fozawpwawv (bwtsvvlice )
Positive
29 Mar 2024
Phase 1/2
70
agbtgcjowb(zpgbttfuoc) = wigtigncxo desvcjlstx (xqkhfkdmoa )
Positive
11 Oct 2023
agbtgcjowb(zpgbttfuoc) = nvbdzxngbc desvcjlstx (xqkhfkdmoa )
Phase 2
Neoplasms
CXCL16 | TNFRSF1A | ITGAX ...
30
vaoizcbrcy(gxylbclnht) = uvorflbjyz olaxkouvkm (vovzcwsubf )
Positive
07 Nov 2022
vaoizcbrcy(gxylbclnht) = aizvefdqje olaxkouvkm (vovzcwsubf )
Phase 1
35
jzhfnezjed(twoivpwrex) = For TPST-1120 monotherapy, the most common treatment related AEs (TRAEs) were nausea (20%), fatigue (15%), and diarrhea (10%), all Grade 1-2. One monotherapy subject (5%) experienced a Grade 3 TRAE (hypertension). In the combination cohort the most common TRAEs related to either drug were fatigue (40%), diarrhea (27%) and nausea (20%), all Grade 1-2. Three combination subjects (19%) experienced Grade 3 TRAEs (one each arthralgia, hepatic enzyme increased, muscle spasms). zqsdqpuohr (kaxaqkrvxe )
Positive
02 Jun 2022
Phase 1
Advanced cancer
FAO/PPARα gene expression
338
TPST-1120 as a single agent
adyrmhmiza(ulsbkhkfig) = osymqgrecc rjnrxxblye (nmfauiwjcr )
Positive
01 Nov 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free